大華股份(002236.SZ):隨着AI大模型與多模態的技術發展,公司有望走出2022年的低谷
格隆匯5月26日丨大華股份(002236.SZ)在5月26日特定對象調研時表示,2023年,公司將以高績效為牽引,由穩轉進,集中一切精力抓業務、謀發展。在數字中國的大背景下,數據的重要性已經形成社會共識,將成為一種重要生產力,其中感知對於數據起到了基礎與核心的作用。近年來,公司持續深化高質量發展、多維生態建設、精細化管理等理念,配合AI技術進一步打磨產品與解決方案競爭力,嘗試打造更多重量級爆款產品及方案,更大程度提升客户滿意度,全方位賦能千行百業數字化轉型。未來,隨着AI大模型與多模態的技術發展,以及和中移良好合作的背景下,公司有望走出2022年的低谷。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.